Continue to slide 2 »

#10. Verve Therapeutics Inc (VERV) — 248% UPSIDE

Company Name:  Verve Therapeutics Inc
Sector:  Drugs & Pharmaceuticals

Verve Therapeutics is a genetic medicines company developing an approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Co.'s primary product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver. PCSK9 is a validated target that plays a critical role in controlling blood low-density lipoprotein cholesterol through its regulation of the low-density lipoprotein receptor. Co.'s second program is designed to turn off the ANGPTL3 gene in the liver. ANGPTL3 is a main regulator of cholesterol and triglyceride metabolism. The median 12 month forward target price among analysts covering VERV is $25.0/share.

Continue to slide 2 »
Quiz: Are You Ready To Invest In Stocks?
Famous Investing Quotes To Live By
The 15 Largest Companies In America
24 Growth Stocks For '24
16 Cheap Stock Gambles Under $10
5 Stocks On Fire Since Five Years Ago
10 Stocks That Grew $10K To $100K+
20 Stocks That Delivered For 20 Years
11 Dividend Champions Poised To Pop
The 10 Best Dow Stocks
Real Estate With Upside: 20 Stock Picks
5 'Coffee Can Stocks' Led To Riches
Eye-Popping Real Estate Yields
10 ETFs Getting Slammed
5 Toxic Stocks Analysts Hate
15 Stock Leaders Since 2019
14 Tech Stocks To Buy Now
17 Investments with a Conscience
Energy Stocks To Power Your Portfolio
10 Five-Year Stock Gold Mines
The Five S&P 500 10-Year Monsters
10 Stocks I Wish You Bought 20 Years Ago
Heal Your Portfolio With Healthcare
2-Decade Stock Winners Since 2004
10 Financially Rewarding Financials
Ten Crazy-High Yielders
Mining $$$ With Metals Stocks
Swing-Trade These Highly Volatile Stocks
Fifteen Huge Winners Since 2014
ETFs on a Three Month Tear
Are You Ready To Beat The Market?
Quotes delayed 20 minutes
 

16 Cheap Stock Gambles Under $10 - Page 1 | www.InvestHELP.net | Copyright © 2018 - 2024, All Rights Reserved

Nothing in InvestHELP.net is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.